Sugi Predict

Sugi Predict / Compounds / SCHEMBL988152

SCHEMBL988152

SCHEMBL988152

O=Cc1ccc(C(=O)O)cc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ P4HB P07237 1/20 0.45
▸ ERN1 O75460 5/20 0.44
▸ ALDH1A1 P00352 2/20 0.42
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ RXRG P48443 1/20 0.42
▸ SRD5A2 P31213 3/20 0.42
▸ UNG P13051 1/20 0.42
▸ TTR P02766 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ ADH5 P11766 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ APEX1 P27695 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PTGFR P43088 1/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16094381 0.84 SMN1; SMN2 (0.45) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL17978937 0.80 NOTUM (0.59) P4HBERN1ALDH1A1L3MBTL1
SCHEMBL827082 0.79 RXRA (0.48) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL31319449 0.79 RXRA (0.48) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL11828554 0.77 RXRA (0.47) SMN1; SMN2P4HBALDH1A1RXRARXRB
SCHEMBL336261 0.77 ADH5 (0.54) SMN1; SMN2P4HBRXRARXRBRXRG
SCHEMBL7026695 0.77 CES2 (0.50) SMN1; SMN2P4HBALDH1A1RXRARXRB
SCHEMBL29193282 0.77 FBP1 (0.53) SMN1; SMN2P4HBALDH1A1TDP1POLB
SCHEMBL989140 0.77 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1POLBL3MBTL1
SCHEMBL29193278 0.77 FBP1 (0.53) SMN1; SMN2P4HBALDH1A1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173421-A1 MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY SEAGEN INC. 2024-05-30 — — US disclosed
EP-4326333-A1 MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY Seagen Inc. (US) 2024-02-28 — — EP disclosed
CN-117597150-A Modulation of antibody dependent cellular cytotoxicity 思进公司 2024-02-23 — — CN disclosed
WO-2022226100-A1 MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY SEAGEN INC. (US) 2022-10-27 — — WO disclosed
WO-2022226100-A1 MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY SEAGEN INC. (US) 2022-10-27 — — WO disclosed
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
CN-107074828-B Compounds and compositions as RAF kinase inhibitors 诺华股份有限公司 2020-05-19 — — CN disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
US-20150152047-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
US-20150152047-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
US-20150152047-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
EP-2842939-A1 BENZAMIDE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2015-03-04 — — EP disclosed
EP-2842939-A1 BENZAMIDE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2015-03-04 — — EP disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2013149997-A1 SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS ALMIRALL, S.A. (ES) 2013-10-10 — — WO disclosed
WO-2011008788-A1 FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF ZHANG DAWEI (US) 2011-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152047-A1 BENZAMIDE DERIVATIVE CYP3A5, HDAC6, BRD1 SMN1; SMN2 2867/4885P4HB 994/4885ERN1 4128/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885ERN1 876/4885
US-20240173421-A1 MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY CD47, CD2, SSB SMN1; SMN2 1081/4885P4HB 1013/4885ERN1 2954/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885P4HB 3679/4885ERN1 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.